Last reviewed · How we verify
Placebo/ Duration of Treatment: 156 weeks
Placebo/ Duration of Treatment: 156 weeks is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development.
Placebo is an inert substance with no active pharmacological mechanism.
At a glance
| Generic name | Placebo/ Duration of Treatment: 156 weeks |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo serves as a control comparator in clinical trials to establish the efficacy of an active investigational drug by comparison. It contains no active pharmaceutical ingredient and produces therapeutic effects only through psychological mechanisms (placebo effect). In this Phase 3 trial context, placebo allows for blinded assessment of the true efficacy of the experimental treatment over 156 weeks.
Approved indications
Common side effects
Key clinical trials
- Effect of Aromatherapy on Perioperative Anxiety Level in Cesarean Sections (NA)
- A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo/ Duration of Treatment: 156 weeks CI brief — competitive landscape report
- Placebo/ Duration of Treatment: 156 weeks updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI